Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

被引:7
|
作者
Rosen, Jeffrey B. [1 ]
Ballantyne, Christie M. [2 ,3 ]
Hsueh, Willa A. [4 ]
Lin, Jianxin [5 ]
Shah, Arvind K. [5 ]
Lowe, Robert S. [5 ]
Tershakovec, Andrew M. [5 ]
机构
[1] Clin Res South Florida, Coral Gables, FL 33134 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA
[4] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
来源
LIPIDS IN HEALTH AND DISEASE | 2015年 / 14卷
关键词
TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR RISK; HYPERCHOLESTEROLEMIA; EZETIMIBE; DYSLIPIDEMIA; COMBINATION; MANAGEMENT; SIMVASTATIN; PREVENTION; SUBCLASSES;
D O I
10.1186/s12944-015-0075-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Metabolic syndrome (MetS) and insulin resistance (IR) are increasing in prevalence, are associated with higher risk for coronary heart disease (CHD), and may potentially influence the responses to lipid-altering drug therapy. This study evaluated the effects of MetS factors (abdominal obesity, depleted high-density lipoprotein cholesterol [HDL-C], and elevated triglycerides, blood pressure, and fasting glucose) and IR on ezetimibe/simvastatin and atorvastatin treatment efficacy in patients with MetS. Methods: This post-hoc analysis of a multicenter, 6-week, double-blind, randomized, parallel group study of 1128 subjects with hypercholesterolemia, MetS, and moderately high/high CHD risk evaluated the effects of baseline MetS factors/IR on percent change from baseline in lipids, apolipoproteins, and high-sensitivity C-reactive protein (hs-CRP), after treatment with the usual starting doses of ezetimibe/simvastatin (10/20 mg) versus atorvastatin (10 mg, 20 mg) and next higher doses (10/40 mg versus 40 mg). Results: Ezetimibe/simvastatin and atorvastatin efficacy was generally consistent across MetS factor/IR subgroups. Ezetimibe/simvastatin produced greater incremental percent reductions in LDL-C, non-HDL-C, apolipoprotein B, total cholesterol, and lipoprotein ratios for all subgroups, and larger percent increases in HDL-C and apolipoprotein AI for all but non-obese and HDL-C >= 40 mg/dL subgroups than atorvastatin at the doses compared. Triglycerides, very-LDL-C, and hs-CRP results were more variable but similar between treatment groups. Conclusion: The magnitude of lipid-altering effects produced by each treatment regimen was generally similar across all MetS and IR subgroups. Ezetimibe/simvastatin produced greater percent reductions in most lipid fractions than atorvastatin at the dose comparisons studied, and all treatments were generally well tolerated.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome
    Jimenez, J. G.
    Rosen, J. B.
    Pirags, V.
    Massaad, R.
    Hanson, M. E.
    Brudi, P.
    Triscari, J.
    DIABETES OBESITY & METABOLISM, 2013, 15 (06) : 513 - 522
  • [22] Impact of pemafibrate on lipid profile and insulin resistance in hypertriglyceridemic patients with coronary artery disease and metabolic syndrome
    Nakamura, Akihiro
    Kagaya, Yuta
    Saito, Hiroki
    Kanazawa, Masanori
    Sato, Kenjiro
    Miura, Masanobu
    Kondo, Masateru
    Endo, Hideaki
    HEART AND VESSELS, 2024, 39 (06) : 486 - 495
  • [23] Metabolic syndrome: frequency of its components and global risk for coronary heart disease
    Ignacio Coniglio, Raul
    Nellem, Jorge
    Sibechi, Norberto
    Colombo, Osvaldo
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2011, 45 (03): : 413 - 421
  • [24] Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome
    Deushi, Michiyo
    Nomura, Mitsunori
    Kawakami, Akio
    Haraguchi, Mihoko
    Ito, Mizuho
    Okazaki, Mitsuyo
    Ishii, Hideto
    Yoshida, Masayuki
    FEBS LETTERS, 2007, 581 (29): : 5664 - 5670
  • [25] Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
    Averna, Maurizio
    Missault, Luc
    Vaverkova, Helena
    Farnier, Michel
    Viigimaa, Margus
    Dong, Qian
    Shah, Arvind
    Johnson-Levonas, Amy O.
    Taggart, William
    Brudi, Philippe
    DIABETES & VASCULAR DISEASE RESEARCH, 2011, 8 (04) : 262 - 270
  • [26] Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease
    Nakamura, Akihiro
    Sato, Kenjiro
    Kanazawa, Masanori
    Kondo, Masateru
    Endo, Hideaki
    Takahashi, Tohru
    Nozaki, Eiji
    HEART AND VESSELS, 2019, 34 (06) : 916 - 925
  • [27] Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study)
    Robinson, Jennifer G.
    Ballantyne, Christie M.
    Hsueh, Willa
    Rosen, Jeffrey
    Lin, Jianxin
    Shah, Arvind
    Lowe, Robert S.
    Hanson, Mary E.
    Tershakovec, Andrew M.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2011, 5 (06) : 474 - 482
  • [28] Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease
    Akihiro Nakamura
    Kenjiro Sato
    Masanori Kanazawa
    Masateru Kondo
    Hideaki Endo
    Tohru Takahashi
    Eiji Nozaki
    Heart and Vessels, 2019, 34 : 916 - 925
  • [29] Glycemia and Cognitive Function in Metabolic Syndrome and Coronary Heart Disease
    Avadhani, Radhika
    Fowler, Kristen
    Barbato, Corinne
    Thomas, Sherine
    Wong, Winnie
    Paul, Camille
    Aksakal, Mehmet
    Hauser, Thomas H.
    Weinger, Katie
    Goldfine, Allison B.
    AMERICAN JOURNAL OF MEDICINE, 2015, 128 (01) : 46 - 55
  • [30] Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease
    Gupta, Milan
    Szmitko, Paul E.
    Tsigoulis, Michelle
    Braga, Manoela F. B.
    Kajil, Mahesh
    Herjikaka, Sheriar
    Quan, Adrian
    Teoh, Hwee
    Verma, Subodh
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 56 (03) : 241 - 245